Abstract
The clinical efficacy of aclarubicin, an anthracycline antibiotic, was studied in 48 patients with leukemia. The antibiotic was used in the following combinations with cytarabine: "7 + 7", "5 + 5" and "7 & 3". A complete remission was stated in 14 (42.4 per cent) out of 33 patients with acute nonlymphoid leukemia, 6 (43 per cent) out of the 14 patients having relapses. The combined therapy was effective in 4 out of 5 pre-resistant patients. The "7 + 3" scheme was the most beneficial. The most common adverse reactions were nausea and vomiting.
Publication types
-
Clinical Trial
-
Comparative Study
-
Controlled Clinical Trial
-
English Abstract
MeSH terms
-
Aclarubicin / administration & dosage*
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Blast Crisis / drug therapy*
-
Cytarabine / administration & dosage*
-
Humans
-
Leukemia / drug therapy*
-
Leukemia, Monocytic, Acute / drug therapy
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
-
Leukemia, Myeloid, Acute / drug therapy
-
Leukemia, Myelomonocytic, Acute / drug therapy
-
Middle Aged
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
-
Remission Induction